Pioneering cellular medicines for women’s health
We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis.
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.
Some of our partners
Latest news
Prof. Alan Trounson to present lecture at KAUST on immune cell therapies for women’s health
By Christine Filippis / February 3, 2026
Cartherics is pleased to announce that Professor Alan Trounson AO, Deputy Chair, will deliver an invited lecture at King Abdullah...
Read More
Cartherics to present at the ANZ Biologics Festival 2026
By Christine Filippis / February 2, 2026
Cartherics is pleased to announce that Dr Madeline Cao, Head of Manufacturing Development and Dr Walid Azar, Chief Scientific Officer,...
Read More
Cartherics granted key patent in China for TAG-72 CAR gene-modified stem cells
By Christine Filippis / January 29, 2026
Melbourne, Australia, 29 January 2026 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases,...
Read More
